# Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

> **NCT04849351** · PHASE2 · COMPLETED · sponsor: **Hutchison Medipharma Limited** · enrollment: 178 (actual)

## Conditions studied

- Marginal Zone Lymphoma
- Follicular Lymphoma

## Interventions

- **DRUG:** HMPL-689

## Key facts

- **NCT ID:** NCT04849351
- **Lead sponsor:** Hutchison Medipharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-15
- **Primary completion:** 2024-02-29
- **Final completion:** 2024-02-29
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2025-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04849351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04849351, "Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04849351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*